PMID- 19550123
OWN - NLM
STAT- MEDLINE
DCOM- 20091022
LR  - 20171116
VI  - 28
IP  - 2
DP  - 2009 Feb
TI  - Biological characteristics of dendritic cells derived from peripheral blood of 
      patients with epithelial ovarian cancer.
PG  - 132-7
AB  - BACKGROUND AND OBJECTIVE: Dendritic cells (DCs) are thought to be the most potent 
      antigen-presenting cells (APC) and play a vital role in stimulating human immune 
      response against cancer. At present, most data concerning the immuno-biological 
      function of DCs are obtained from healthy donors. The information about the 
      biological characteristics of DCs from patients is limited. In this study, the 
      biological characteristics of monocyte-derived dendritic cells (MoDCs) from 
      patients with ovarian cancer were investigated. METHODS: Monocytes were isolated 
      from peripheral blood mononuclear cells (PBMC) of eight epithelial ovarian cancer 
      patients and 13 healthy women volunteers, cultured with interleukin 4 (IL-4) and 
      granulocyte-macrophage colony stimulating factor (GM-CSF), and stimulated with 
      tumor necrosis factor-alpha (TNF-alpha). At seven days after induction, the 
      morphologic characteristics of MoDCs were observed. The features of phenotype 
      were analyzed using flow cytometry. The ability of MoDCs to stimulate 
      proliferation of lymphocytes was tested by allogeneic mixed leukocytes reaction 
      (MLR). RESULTS: Mature MoDCs with typical morphology were obtained after seven 
      days of culture. MoDCs from both patients and healthy women expressed high levels 
      of HLA-ABC (MHC-I), HLA-DR (MHC-II) and large amounts of CD86 and CD80. There was 
      no significant differences between MoDCs from ovarian cancer women and healthy 
      women in the mean fluorescence intensity (MFI) of HLA-ABC, HLA-DR, CD86 and CD80 
      (p > 0.05). The MLR was significantly weaker in ovarian cancer patients than in 
      healthy women (p < 0.05). CONCLUSION: MoDCs from ovarian cancer patients may 
      present lower capacity of stimulating proliferation of lymphocytes, indicating 
      that the patients' MoDCs may have immunological function defect at certain 
      extent.
FAU - Lan, Chun-Yan
AU  - Lan CY
AD  - State Key Laboratory of Oncology in South China, Department of Gynecologic 
      Oncology, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
FAU - Liu, Ji-Hong
AU  - Liu JH
FAU - Xia, Jian-Chuan
AU  - Xia JC
FAU - Zheng, Li-Min
AU  - Zheng LM
LA  - eng
PT  - Journal Article
DEP - 20090227
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - B7-1 Antigen/analysis
MH  - B7-2 Antigen/analysis
MH  - Cell Separation
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/drug effects/*immunology
MH  - Epithelial Cells/pathology
MH  - Female
MH  - Flow Cytometry
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - HLA-A Antigens/analysis
MH  - HLA-B Antigens/analysis
MH  - HLA-C Antigens/analysis
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-4/pharmacology
MH  - Lymphocyte Culture Test, Mixed
MH  - Middle Aged
MH  - Monocytes/cytology/drug effects/*immunology
MH  - Ovarian Neoplasms/*blood/immunology/pathology
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Young Adult
EDAT- 2009/06/25 09:00
MHDA- 2009/10/23 06:00
CRDT- 2009/06/25 09:00
PHST- 2009/06/25 09:00 [entrez]
PHST- 2009/06/25 09:00 [pubmed]
PHST- 2009/10/23 06:00 [medline]
AID - 8427 [pii]
PST - ppublish
SO  - Ai Zheng. 2009 Feb;28(2):132-7. Epub 2009 Feb 27.